Abstract: A health monitor, comprising: an electrode that includes a hydrogel composition comprising a first network that comprises at least two hydroxyl-bearing chains of a first polymer, the at least two hydroxyl-bearing polymer chains being crosslinked by crosslinks that comprise one or more boronic ester bonds; and at least one conductive additive dispersed within the composition, the electrode being configured for patient contact. Also provided are related methods.

Abstract: A method is provided for characterising and/or prognosing prostate cancer in a subject comprising measuring the level of at least one protein from a panel or at least one peptide thereof in a sample from the subject. The method may be used to determine the grade and stage of the prostate cancer. Also disclosed is a method for selecting a treatment for prostate cancer, together with corresponding methods of treatment. Systems and computing devices for performing the methods are also provided.

Abstract: A method is provided for characterising and/or prognosing prostate cancer in a subject comprising measuring the level of at least one protein from a panel or at least one peptide thereof in a sample from the subject. The method may be used to determine the grade and stage of the prostate cancer. Also disclosed is a method for selecting a treatment for prostate cancer, together with corresponding methods of treatment. Systems and computing devices for performing the methods are also provided.

Abstract: A method of automatically selecting tests for execution on a software product includes generating a cost model based on test performance history data that is based on results of past executions of a plurality of tests on the software product, wherein the cost model provides, for each test in the plurality of tests, a first expected monetary cost value associated with executing the test and a second expected monetary cost value associated with skipping execution of the test. The method includes automatically selecting tests in the plurality of tests for future execution based on the first and second expected monetary cost values.

Abstract: A follow-me application can be configured to generate a follow-me identifier (ID) that uniquely identifies a particular route traveled by a computing device executing the follow-me application. The follow-me application can also be configured to determine route data for the particular route traveled. The route data characterizes turn-by-turn directions to facilitate travel along the particular route by another computing device.

Abstract: Embodiments of the invention are directed to group aggregation leveraging methods and systems for consumers to buy products from a broker. The broker offers a product to consumers for a first fixed price for a predetermined time period. Once a predetermined number of consumers commit to purchasing the product (i.e., reach a threshold), the consumers receive the same product at a second fixed price wherein the second fixed price is less than the first fixed price. Once the threshold is met, each committed consumer receives an alert from the broker that the consumer will receive the same product at the new reduced price (second fixed price). This process is repeated until the predetermined time period expires or inventory of the product is depleted. Consumers may leverage their collective group buying power by communicating to others that the product is available for the predetermined time period through social media or any other suitable means.

Abstract: Systems and methods for determining related node failures in a multi-node system use log data obtained from the nodes. This log data is processed in various ways to indicate clusters of nodes that experience related failures.

Abstract: This invention provides systems and methods that minimize or remove human intervention during the payment media handling process on the shop floor, in the back office and at the cash-in-transit place. By automating processes and providing physical, tamper evident secure means for transporting the payment media, it is possible to limit, if not remove, the need for retail staff to handle payment media This invention also provides systems and methods that enable the retailer to count, reconcile and prepare the payment media in a format that is acceptable to the commercial banks. This invention further provides systems and methods for a secure audit trail that detail payment media movement from the payment media originating source to the bank.

Abstract: The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.

Abstract: This invention provides systems and methods that minimize or remove human intervention during the payment media handling process on the shop floor, in the back office and at the cash-in-transit place. By automating processes and providing physical, tamper evident secure means for transporting the payment media, it is possible to limit, if not remove, the need for retail staff to handle payment media This invention also provides systems and methods that enable the retailer to count, reconcile and prepare the payment media in a format that is acceptable to the commercial banks. This invention further provides systems and methods for a secure audit trail that detail payment media movement from the payment media originating source to the bank.

Abstract: This invention provides systems and methods that minimize or remove human intervention during the payment media handling process on the shop floor, in the back office and at the cash-in-transit place. By automating processes and providing physical, tamper evident secure means for transporting the payment media, it is possible to limit, if not remove, the need for retail staff to handle payment media This invention also provides systems and methods that enable the retailer to count, reconcile and prepare the payment media in a format that is acceptable to the commercial banks. This invention further provides systems and methods for a secure audit trail that detail payment media movement from the payment media originating source to the bank.

Abstract: This invention provides systems and methods that minimize or remove human intervention during the payment media handling process on the shop floor, in the back office and at the cash-in-transit place. By automating processes and providing physical, tamper evident secure means for transporting the payment media, it is possible to limit, if not remove, the need for retail staff to handle payment media. This invention also provides systems and methods that enable the retailer to count, reconcile and prepare the payment media in a format that is acceptable to the commercial banks. This invention further provides systems and methods for a secure audit trail that detail payment media movement from the payment media originating source to the bank.

Abstract: This invention provides systems and methods that minimize or remove human intervention during the payment media handling process on the shop floor, in the back office and at the cash-in-transit place. By automating processes and providing physical, tamper evident secure means for transporting the payment media, it is possible to limit, if not remove, the need for retail staff to handle payment media This invention also provides systems and methods that enable the retailer to count, reconcile and prepare the payment media in a format that is acceptable to the commercial banks. This invention further provides systems and methods for a secure audit trail that detail payment media movement from the payment media originating source to the bank.

Abstract: The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.

Abstract: The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.

Abstract: The present invention relates to a dry blend, used for forming azithromycin tablets by direct compression, comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. This invention also relates to an azithromycin tablet comprising non-dihydrate azithromycin and at least one pharmaceutically acceptable excipient. Preferably, the azithromycin tablet is formed by directly compressing the dry blend, of the present invention, to form said azithromycin tablet. Preferably, the azithromycin tablet, of the present invention, contains a dosage of 250 mgA, 500 mgA or 600 mgA of azithromycin. This invention further relates to an azithromycin tablet which is produced by forming a dry blend of a non-granulated azithromycin form A and at least one pharmaceutically acceptable excipient. The azithromycin tablet is then formed by directly compressing the dry blend.